Class A Common Stock

Class A Common Stock

Class A Common Stock

Class A Common Stock

Restricted Stock Units granted September 1, 2023 pursuant to the Albany International Corp. 2023 Incentive Plan.  Each Restricted Stock Unit entitles the holder to receive one share of Class A Common stock at the time of vesting.

2500 Restricted Stock Units vest on March 1, 2024; 2500 Restricted Stock Units vest on March 1, 2025; and 2500 Restricted Stock Units vest on March 1, 2026.

6786 Restricted Stock Units vest on March 1, 2024; 6786 Restricted Stock Units vest on March 1, 2025; and 6786 Restricted Stock Units vest on March 1, 2026.

Restricted Stock Units granted February 23, 2024 pursuant to the Albany International Corp. 2023 Incentive Plan.  Each Restricted Stock Unit entitles the holder to receive one share of Class A Common stock at the time of vesting.

3377 Restricted Stock Units vest on March 1, 2025; 3377 Restricted Stock Units vest on March 1, 2026; and 3377 Restricted Stock Units vest on March 1, 2027.

Restricted Stock Units granted February 21, 2025 pursuant to the Albany International Corp. 2023 Incentive Plan.  Each Restricted Stock Unit entitles the holder to receive one share of Class A Common stock at the time of vesting.

5450 Restricted Stock Units vest on March 1, 2026; 5450 Restricted Stock Units vest on March 1, 2027; and 5449 Restricted Stock Units vest on March 1, 2028.

Cynthia A. SantaBarbara, Attorney-in-Fact


Common Stock

The sale was made pursuant to a 10b5-1 Plan adopted by the reporting person on March 10, 2025.

Options previously granted under the Registrant's 2019 Management Incentive Plan. Each option represents the right to receive upon exercise one share of the Registrant's common stock subject to the applicable vesting and settlement conditions.

The June 12, 2019 stock option grant vested in substantially equal annual installments over five years starting March 28, 2020, and was fully vested on March 28, 2024.

Approximately 31% represents time-based options which vested in substantially equal annual installments over five years starting March 28, 2020 and approximately 69% represents performance-based options, of which 25% vested upon the initial public offering and the remainder will be eligible for vesting upon satisfaction of certain performance criteria including stock price performance.


Common Stock

Common Stock

Common Stock

Common Stock

Restricted stock units vested and converted to shares of common stock on a one-for-one basis.

On August 1, 2022, the reporting person was granted 5,574 restricted stock units that vest in three equal annual installments beginning on the first anniversary of the grant date

On August 1, 2023, the reporting person was granted 4,011 restricted stock units that vest in three equal annual installments beginning on the first anniversary of the grant date.

On August 1, 2024, the reporting person was granted 3,374 restricted stock units that vest in three equal annual installments beginning on the first anniversary of the grant date.

Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.

Subject to the reporting person's continued employment with the issuer through the applicable vesting date, these restricted stock units are scheduled to vest in equal installments on each of August 1, 2026, August 1, 2027 and August 1, 2028 and will be settled, with respect to vested restricted stock units, in shares of the issuer's common stock no later than 30 days after each applicable vesting date.

/s/ Craig D. Apolinsky, Attorney-in-Fact for George T. Hendren


Reflects the forfeiture of shares of restricted stock of Clearway Energy, Inc. (the "Issuer") previously granted by Clearway Energy Group LLC ("Clearway Energy Group") under its Long Term Equity Incentive Program to one or more of its employees.

The securities reported herein are held directly by Clearway Energy Group. GIP III Zephyr Acquisition Partners, L.P. ("Zephyr") is the sole member of Clearway Energy Group. Zephyr Holdings GP, LLC ("Zephyr GP") is the general partner of Zephyr.

TotalEnergies Renewables USA, LLC holds 50% of the equity interests in Zephyr GP. TotalEnergies Holdings USA, Inc. is the sole shareholder of TotalEnergies Delaware, Inc., which is the sole member of TotalEnergies Renewables USA, LLC. TotalEnergies Gestion USA SARL, which is a direct wholly owned subsidiary of TotalEnergies SE, is the sole shareholder of TotalEnergies Holdings USA, Inc. Each of the foregoing entities is a "Reporting Person" and may be deemed to beneficially own the securities reported herein; however, each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein. Solely for purposes of Section 16 of the Exchange Act, each Reporting Person may be deemed a "director by deputization".


The reporting person has elected to receive fully vested shares of the Issuer's common stock in lieu of cash retainer fees payable for service on the Issuer's Board of Directors and any committees thereof. The number of shares issued represents the quotient of (A) the amount of such fees divided by (B) the Issuer's closing stock price on the date such fees would otherwise be paid, rounded up to the nearest whole share.


/s/ Jaileah X. Huddleston, Attorney-in-Fact for Brad S. Lakhia


Includes shares acquired under the Motorola Solutions Employee Stock Purchase Plan and through the reinvestment of dividends.

Alejandro Dieguez, on behalf of Kathryn A. Moore, Senior Vice President, Human Resources (Power of Attorney on File)


Common Stock

Common Stock

Common Stock

Includes 160 shares acquired by the Reporting Person on June 30, 2025 pursuant to the GMS Inc. Employee Stock Purchase Plan.

On August 1, 2023, the reporting person was granted 1,521 restricted stock units that vest in three equal annual installments beginning on the first anniversary of the grant date.

On August 1, 2024, the reporting person was granted 1,404 restricted stock units that vest in three equal annual installments beginning on the first anniversary of the grant date.

Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock

/s/ Craig D. Apolinsky, Attorney-in-Fact for Leigh R. Dobbs


Common Stock

Common Stock

Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer.

The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of August 1, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.

Exercisable with respect to 25% of the shares subject to the option vesting in four equal installments on the first, second, third and fourth anniversaries of August 1, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.


By William F Griffin Jr Revocable Trust U/A DTD FBO 12/09/04

On August 5, 2025, the Reporting Person transferred 80,0000 shares from the William F. Griffin 2025 GRAT Trust to the William F Griffin Jr Revocable Trust.


Common Stock

Common Stock

Common Stock

Common Stock

Restricted stock units vested and converted to shares of common stock on a one-for-one basis.

Includes 296 shares acquired by the Reporting Person on June 30, 2025 pursuant to the GMS Inc. Employee Stock Purchase Plan.

On August 1, 2022, the reporting person was granted 5,574 restricted stock units that vest in three equal annual installments beginning on the first anniversary of the grant date.

On August 1, 2023, the reporting person was granted 3,677 restricted stock units that vest in three equal annual installments beginning on the first anniversary of the grant date.

On August 1, 2024, the reporting person was granted 3,104 restricted stock units that vest in three equal annual installments beginning on the first anniversary of the grant date.

Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.

Subject to the reporting person's continued employment with the issuer through the applicable vesting date, these restricted stock units are scheduled to vest in equal installments on each of August 1, 2026, August 1, 2027 and August 1, 2028 and will be settled, with respect to vested restricted stock units, in shares of the issuer's common stock no later than 30 days after each applicable vesting date.


Represents shares that have been withheld by the Issuer to satisfy income tax withholding and remittance obligations in connection with the vesting of restricted stock units.

These shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 11, 2025.


The reporting person has elected to receive fully vested shares of the Issuer's common stock in lieu of cash retainer fees payable for service on the Issuer's Board of Directors and any committees thereof.  The number of shares issued represents the quotient of (A) the amount of such fees divided by (B) the Issuer's closing stock price on the date such fees would otherwise be paid, rounded up to the nearest whole share.


These restricted stock units, which convert into common stock on a one-for-one basis ("RSUs"), were granted under the issuer's 2018 Omnibus Equity Compensation Plan and, except as otherwise provided in the award agreement, vest in 12 equal quarterly increments over a period of 36 months from the date of grant.

Includes 22,156 unvested RSUs and 1,391 shares of common stock.


Represents 8,814 shares granted as equity compensation that vest immediately.


Common Stock

The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 25, 2024.

Certain of these securities listed in Column 5 are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions of each RSU.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.88 to $78.29. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

1/36th of the shares subject to the option shall vest on September 20, 2022 and at the end of each successive one-month period thereafter, subject to the Reporting Person continuing as a service provider through each such date.


Common Stock

Common Stock

Common Stock

Common Stock

Restricted stock units vested and converted into common stock on a one-for-one basis.

Includes 235 shares acquired by the Reporting Person on June 30, 2025 pursuant to the GMS Inc. Employee Stock Purchase Plan.

On August 1, 2022, the reporting person was granted 9,290 restricted stock units that vest in three equal annual installments beginning on the first anniversary of the grant date.

On August 1, 2023, the reporting person was granted 5,014 restricted stock units that vest in three equal annual installments beginning on the first anniversary of the grant date.

On August 1, 2024, the reporting person was granted 4,454 restricted stock units that vest in three equal annual installments beginning on the first anniversary of the grant date.

Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.

Subject to the reporting person's continued employment with the issuer through the applicable vesting date, these restricted stock units are scheduled to vest in equal installments on each of August 1, 2026, August 1, 2027 and August 1, 2028 and will be settled, with respect to vested restricted stock units, in shares of the issuer's common stock no later than 30 days after each applicable vesting date.

/s/ Craig D. Apolinsky, Attorney-in-Fact for Scott M. Deakin


The reporting person acquired 2,000,000 shares of the issuer's common stock pursuant to a Stock Purchase Agreement, dated as of August 1, 2025, between the issuer and the reporting person, for an aggregate purchase price of $40,000.


Received pursuant to Issuer's Directors' Stock Award Plan for service as a director - exempt transaction under Rule 16b-3 (d).

N/A.

/s/ Andres C. Ferrero , Attorney-in-Fact


Vincent DePaul Kelly,Trustee of the Vincent DePaul Kelly Fifth Amended and Restated  Revocable Trust

Common Stock

Vincent DePaul Kelly, Trustee of the Vincent DePaul Kelly Fifth Amended and Restated Revocable Trust

Each Restricted Stock Units ("RSUs") represents a contingent right to receive one share of the issuer's Common Stock.


Common Stock


The shares reported herein represent shares acquired in a dividend reinvestment transaction.

Includes 34,065 shares of Class A common stock that are not subject to vesting or transfer restrictions and 20,000 options to purchase Class A common stock that are fully vested and not subject to transfer restrictions.

Includes 21,846 shares of Class B common stock that are not subject to vesting or transfer restrictions and 196,987 options to purchase Class B common stock that are fully vested and not subject to
transfer restrictions.

/s/Allison Zolot as Attorney-in-Fact for Scott Schatz


Executive Vice President, General Counsel and Secretary


Common Stock

The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 27, 2024.

This sale price represents the weighted average sale price of the shares sold ranging from $170.105 to $171.10 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

This sale price represents the weighted average sale price of the shares sold ranging from $171.105 to $172.09 per share. Upon request by the Commission staff, the Issuer, or a security holder of the 1Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

This sale price represents the weighted average sale price of the shares sold ranging from $172.12 to $173.11 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

This sale price represents the weighted average sale price of the shares sold ranging from $173.12 to $174.11 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

This sale price represents the weighted average sale price of the shares sold ranging from $174.12 to $174.195 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

Shares are held by the Klarich 2005 Trust, for which the Reporting Person and his spouse serve as trustees.

The shares subject to the option are fully vested and exercisable.

/s/ Elizabeth Villalobos, Attorney-in-Fact for Lee Klarich


Reflects the forfeiture of shares of restricted stock of the Issuer previously granted by Clearway Energy Group LLC ("Clearway Energy Group") under its Long Term Equity Incentive Program to one or more of its employees.

Reflects securities held directly by Clearway Energy Group. Zephyr Holdings GP, LLC ("Zephyr GP") is the general partner of GIP III Zephyr Acquisition Partners, L.P. ("Zephyr") which is the sole member of Clearway Energy Group. Zephyr GP is owned by GIP III Zephyr Midco Holdings, L.P. ("Midco") and TotalEnergies Renewables USA, LLC. Global Infrastructure Investors III, LLC ("Global Investors") is the sole general partner of Global Infrastructure GP III, L.P. ("Global GP"), which is the general partner of Midco. As a result, each of Zephyr GP, Zephyr, Midco, Global GP and Global Investors (the "GIP Entities") may be deemed to share beneficial ownership of the securities owned by Clearway Energy Group.

Adebayo Ogunlesi, Michael McGhee, Rajaram Rao, Deepak Agrawal, Julie Ashworth, Jonathan Bram, William Brilliant, Matthew Harris, Tom Horton, Sugam Mehta and Salim Samaha, as the voting members of the Investment Committee of Global Investors, may be deemed to share beneficial ownership of the Issuer securities beneficially owned by Global Investors. Such individuals expressly disclaim any such beneficial ownership.

BlackRock Portfolio Management LLC and the GIP Entities disclaim beneficial ownership of the securities reported herein, except to the extent of their respective pecuniary interest therein, if any, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended, BlackRock Portfolio Management LLC and the GIP Entities state that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the securities reported herein for purposes of Section 16 or for any other purpose.

In accordance with SEC Release No. 34-39538 (January 12, 1998), BlackRock Portfolio Management LLC is reporting Issuer securities beneficially owned, or deemed to be beneficially owned, by certain business units (collectively, the "Reporting Business Units") of BlackRock, Inc. and its subsidiaries and affiliates. This filing does not include Issuer securities, if any, beneficially owned by other business units whose beneficial ownership of securities is disaggregated from that of the Reporting Business Units in accordance with such release.

BlackRock Portfolio Management LLC By: /s/ Julie Ashworth, Authorized Signatory


Common Stock

The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2024.

Certain of these securities listed in Column 5 are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions of each RSU.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.75 to $78.115. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.00 to $80.01. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

1/48 of the shares subject to the option shall vest on January 20, 2023 and at the end of each successive one-month period thereafter, subject to the Reporting Person continuing as a service provider through each such date.


On August 3, 2023, the Reporting Person was granted restricted stock units ("RSUs") for 1,695.000 shares of KLA common stock. On August 3, 2025, twenty-five percent (25%) of the RSUs vested. Pursuant to the terms of the grant, shares of KLA common stock were automatically withheld at vesting to cover required tax withholding. The fair market value of KLA common stock used for purposes of calculating the number of shares to be withheld was the closing price of KLA common stock as reported on August 1, 2025.

The number of shares of KLA common stock includes 6,354.194 shares issuable upon vesting of RSUs.

On August 4, 2022, the Reporting Person was granted restricted stock units ("RSUs") for 2,384.000 shares of KLA common stock. On August 4, 2025, twenty-five percent (25%) of the RSUs vested. Pursuant to the terms of the grant, shares of KLA common stock were automatically withheld at vesting to cover required tax withholding. The fair market value of KLA common stock used for purposes of calculating the number of shares to be withheld was the closing price of KLA common stock as reported on August 1, 2025.

The number of shares of KLA common stock includes 5,758.194 shares issuable upon vesting of RSUs.

This sale was effected pursuant to the terms of a Rule 10b5-1 trading plan adopted by the Reporting Person on Februry 7, 2025.

/s/ Jeffrey S. Cannon, as attorney-in-fact for Mary Beth Wilkinson


Common Stock

The option is fully vested.

The Stock Option reported herein as being disposed of is an option to purchase common stock of TransMedics, Inc. Immediately prior to the closing of the Issuer's initial public offering, pursuant to the terms of the Merger Agreement, each outstanding option to purchase shares of common stock of TransMedics, Inc. was converted into an outstanding option to purchase shares of common stock of the Issuer adjusted on a 3.5-for-one basis, with a corresponding adjustment to the exercise price.

By: /s/ Gerardo Hernandez, Attorney-in-Fact


On August 3, 2023, the Reporting Person was granted restricted stock units ("RSUs") for 2,649.000 shares of KLA common stock. On August 3, 2025, twenty-five percent (25%) of the RSUs vested. Pursuant to the terms of the grant, shares of KLA common stock were automatically withheld at vesting to cover required tax withholding. The fair market value of KLA common stock used for purposes of calculating the number of shares to be withheld was the closing price of KLA common stock as reported on August 1, 2025.

The number of shares of KLA common stock includes 7,191.775 shares issuable upon vesting of RSUs.

On August 4, 2022, the Reporting Person was granted restricted stock units ("RSUs") for 2,980.000 shares of KLA common stock. On August 4, 2025, twenty-five percent (25%) of the RSUs vested. Pursuant to the terms of the grant, shares of KLA common stock were automatically withheld at vesting to cover required tax withholding. The fair market value of KLA common stock used for purposes of calculating the number of shares to be withheld was the closing price of KLA common stock as reported on August 1, 2025.

The number of shares of KLA common stock includes 6,446.775 shares issuable upon vesting of RSUs.

/s/ Jeffrey S. Cannon, as attorney-in-fact for Brian Lorig


On August 3, 2023, the Reporting Person was granted restricted stock units ("RSUs") for 15,684.000 shares of KLA common stock. On August 3, 2025, twenty-five percent (25%) of the RSUs vested. Pursuant to the terms of the grant, shares of KLA common stock were automatically withheld at vesting to cover required tax withholding. The fair market value of KLA common stock used for purposes of calculating the number of shares to be withheld was the closing price of KLA common stock as reported on August 1, 2025.

The number of shares of KLA common stock includes 47,666.511 shares issuable upon vesting of RSUs.

On August 4, 2022, the Reporting Person was granted restricted stock units ("RSUs") for 16,097.000 shares of KLA common stock. On August 4, 2025, twenty-five percent (25%) of the RSUs vested. Pursuant to the terms of the grant, shares of KLA common stock were automatically withheld at vesting to cover required tax withholding. The fair market value of KLA common stock used for purposes of calculating the number of shares to be withheld was the closing price of KLA common stock as reported on August 1, 2025.

The number of shares of KLA common stock includes 43,642.511 shares issuable upon vesting of RSUs.

/s/ Jeffrey S. Cannon, as attorney-in-fact for Richard P. Wallace


On August 3, 2023, the Reporting Person was granted restricted stock units ("RSUs") for 635.000 shares of KLA common stock. On August 3, 2025, twenty-five percent (25%) of the RSUs vested. Pursuant to the terms of the grant, shares of KLA common stock were automatically withheld at vesting to cover required tax withholding. The fair market value of KLA common stock used for purposes of calculating the number of shares to be withheld was the closing price of KLA common stock as reported on August 1, 2025.

The number of shares of KLA common stock includes 2,047.000 shares issuable upon vesting of RSUs.

On August 4, 2022, the Reporting Person was granted restricted stock units ("RSUs") for 894.000 shares of KLA common stock. On August 4, 2025, twenty-five percent (25%) of the RSUs vested. Pursuant to the terms of the grant, shares of KLA common stock were automatically withheld at vesting to cover required tax withholding. The fair market value of KLA common stock used for purposes of calculating the number of shares to be withheld was the closing price of KLA common stock as reported on August 1, 2025.

The number of shares of KLA common stock includes 1,824.000 shares issuable upon vesting of RSUs.

This sale was effected pursuant to the terms of a Rule 10b5-1 trading plan adopted by the Reporting Person on February 20, 2025.

/s/ Jeffrey S. Cannon, as attorney-in-fact for Virendra A. Kirloskar


On August 3, 2023, the Reporting Person was granted restricted stock units ("RSUs") for 5,828.000 shares of KLA common stock. On August 3, 2025, twenty-five percent (25%) of the RSUs vested. Pursuant to the terms of the grant, shares of KLA common stock were automatically withheld at vesting to cover required tax withholding. The fair market value of KLA common stock used for purposes of calculating the number of shares to be withheld was the closing price of KLA common stock as reported on August 1, 2025.

The number of shares of KLA common stock includes 15,493.912 shares issuable upon vesting of RSUs.

On August 4, 2022, the Reporting Person was granted restricted stock units ("RSUs") for 6,260.000 shares of KLA common stock. On August 4, 2025, twenty-five percent (25%) of the RSUs vested. Pursuant to the terms of the grant, shares of KLA common stock were automatically withheld at vesting to cover required tax withholding. The fair market value of KLA common stock used for purposes of calculating the number of shares to be withheld was the closing price of KLA common stock as reported on August 1, 2025.

The number of shares of KLA common stock includes 13,928.912 shares issuable upon vesting of RSUs.

/s/ Jeffrey S. Cannon, as attorney-in-fact for Ahmad A. Khan


The number of shares of KLA common stock includes 14,703.912 shares issuable upon vesting of RSUs.

On August 4, 2022, the Reporting Person was granted restricted stock units ("RSUs") for 5,961.000 shares of KLA common stock. On August 4, 2025, twenty-five percent (25%) of the RSUs vested. Pursuant to the terms of the grant, shares of KLA common stock were automatically withheld at vesting to cover required tax withholding. The fair market value of KLA common stock used for purposes of calculating the number of shares to be withheld was the closing price of KLA common stock as reported on August 1, 2025.

The number of shares of KLA common stock includes 13,213.912 shares issuable upon vesting of RSUs.

/s/ Jeffrey S. Cannon, as attorney-in-fact for Bren D. Higgins


The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on March 14, 2025 to cover expected tax liability associated with the vesting of Issuer equity awards.


The price reported in Column 4 is a weighted average price.  The shares were sold in multiple transactions at prices ranging from $106.58 to $107.56, inclusive.  The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within ranges set forth in this footnote.

The price reported in Column 4 is a weighted average price.  The shares were sold in multiple transactions at prices ranging from $107.58 to $108.53, inclusive.  The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within ranges set forth in this footnote.

The price reported in Column 4 is a weighted average price.  The shares were sold in multiple transactions at prices ranging from $108.59 to $109.57, inclusive.  The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within ranges set forth in this footnote.

The price reported in Column 4 is a weighted average price.  The shares were sold in multiple transactions at prices ranging from $109.60 to $110.30, inclusive.  The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within ranges set forth in this footnote.


The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 9, 2025.

This sale price represents the weighted average sale price of the shares sold ranging from $168.44 to $169.42 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

This sale price represents the weighted average sale price of the shares sold ranging from $169.44 to $169.97 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

This sale price represents the weighted average sale price of the shares sold ranging from $170.44 to $171.42 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

This sale price represents the weighted average sale price of the shares sold ranging from $171.44 to $172.43 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

This sale price represents the weighted average sale price of the shares sold ranging from $172.44 to $173.43 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

This sale price represents the weighted average sale price of the shares sold ranging from $173.44 to $174.41 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

This sale price represents the weighted average sale price of the shares sold ranging from $174.44 to $175.42 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

This sale price represents the weighted average sale price of the shares sold ranging from $175.44 to $175.89 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

/s/ Elizabeth Villalobos, Attorney-in-Fact for Nir Zuk


This transaction is not a sale of shares by the Reporting Person. Instead, this represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the vesting and net settlement of previously reported restricted stock units.

/s/ Elizabeth Villalobos, Attorney-in-Fact for Josh D. Paul


The reporting person has elected to receive fully vested shares of the Issuer's common stock in lieu of cash retainer fees payable for service on the Issuer's Board of Directors and any committees thereof.  The number of shares issued represents the quotient of (A) the amount of such fees divided by (B) the Issuer's closing stock price on the date such fees would otherwise be paid, rounded up to the nearest whole share.


Represents the number of shares withheld to cover the cost of taxes upon vesting of restricted stock units granted on August 1, 2023, which was previously reported. The restricted stock units vest 50% annually on the anniversary date of the grant and are fully vested after two years.

/s/ JILL CHAVARRIA, Attorney in Fact for Catrina Harding


Represents 4,651 shares granted as part of equity compensation that vest immediately.


These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units.


The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 5, 2024.

This transaction was executed in multiple trades at prices ranging from $132.77 to $133.68, inclusive. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) of this Form 4.

This transaction was executed in multiple trades at prices ranging from $133.905 to $134.90, inclusive. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) of this Form 4.

This transaction was executed in multiple trades at prices ranging from $134.92 to $135.83, inclusive. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) of this Form 4.

Rooster A. Willis 2019 Trust, Austin Willis Trustee.

Wilder Grace Willis 2019 Trust, Austin Willis Trustee.

Charles F. Willis V 2019 Trust, Austin Willis Trustee.

Austin C. Willis 2019 Irrevocable Trust, Mary Willis Trustee.

Charles F. Willis V 2016 Trust, Austin Willis Trustee.

2019 Willis Family Trust, Austin Willis Trustee.

Includes 213,415 shares having shared voting power of CFW Partners with Charles F. Willis IV.

Shared voting power of CFW Partners with Charles F. Willis IV.


The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.80 to $4.95, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.

/s/ John J. Mitchell, as attorney-in-fact for Adam Munoz


Common Stock

Common Stock

Common Stock

Common Stock

Restricted stock units vested and converted into common stock on a one-for-one basis.

Includes 296 shares acquired by the Reporting Person on June 30, 2025 pursuant to the GMS Inc. Employee Stock Purchase Plan.

On August 1, 2022, the reporting person was granted 28,799 restricted stock units that vest in three equal annual installments beginning on the first anniversary of the grant date.

On August 1, 2023, the reporting person was granted 22,059 restricted stock units that vest in three equal annual installments beginning on the first anniversary of the grant date.

On August 1, 2024, the reporting person was granted 18,893 restricted stock units that vest in three equal annual installments beginning on the first anniversary of the grant date.

Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.

Subject to the reporting person's continued employment with the issuer through the applicable vesting date, these restricted stock units are scheduled to vest in equal installments on each of August 1, 2026, August 1, 2027 and August 1, 2028 and will be settled, with respect to vested restricted stock units, in shares of the issuer's common stock no later than 30 days after each applicable vesting date.

/s/ Craig D. Apolinsky, Attorney-in-Fact for John C. Turner, Jr.


These shares were acquired pursuant to the "match benefit" of ESPP in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).

Represents common shares that have been withheld by the Issuer to satisfy the tax liability in connection with the issuance of shares pursuant to the ESPP's "match benefit."

These shares were acquired under the Liberty Latin America Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).

The Reporting Person received 3,782 shares contributed by Issuer under its 401(k) Plan as of July 31, 2025.

The trading symbols for the Issuer's classes of common shares are LILA, LILAB, and LILAK.


Common stock issued to the reporting Director in lieu of quarterly cash retainer payment.

William E. Matthews, V, CFO, pursuant to power of attorney


The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $110.00 to $110.32, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within ranges set forth in this footnote.


Received pursuant to Issuer's Directors' Stock Award Plan for service as a director - exempt transaction under Rule 16b-3 (d).

N/A.


The Reporting Person received  3,784 shares contributed by Issuer under its 401(k) Plan as of July 31, 2025.


Common Stock, par value $.01 per share

The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 18, 2023.

The price reported in Column 4 is a weighted average price. These shares of Iron Mountain Incorporated common stock ("Common Stock") were sold in multiple transactions at prices ranging from $93.500 to $94.440, inclusive. The Reporting Person undertakes to provide Iron Mountain Incorporated (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares of Common Stock sold at each separate price within the ranges set forth in this footnote (2).

The price reported in Column 4 is a weighted average price. These shares of Common Stock were sold in multiple transactions at prices ranging from $94.510 to $95.502, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares of Common Stock sold at each separate price within the ranges set forth in this footnote (3).

The price reported in Column 4 is a weighted average price. These shares of Common Stock were sold in multiple transactions at prices ranging from $95.512 to $96.470, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares of Common Stock sold at each separate price within the ranges set forth in this footnote (4).

Balance reflects 295,650 shares transferred from the Grantor for funding of a Grantor Retained Annuity Trust on November 29, 2024. This transfer is exempt from Section 16 pursuant to Rule 16a-13.

This stock option, representing a right to purchase a total of 829,506 shares, is fully vested.

/s/ Christine Zhang, under Power of Attorney dated February 27, 2025, from William Meaney


The transaction reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 28, 2025.

The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from  $26.348 to $26.710, inclusive.  The reporting person undertakes to provide MGIC Investment Corporation, any security holder of MGIC Investment Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.


/s/ Lori A. Castillo, By Power of Attorney


/s/ Kathy L. Uttley as attorney-in-fact for Austin Scott Miller


These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units.

/s/ Jeffrey Adam Novack, Attorney-in-Fact


These shares were acquired pursuant to the "match benefit" of ESPP in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).

Represents common shares that have been withheld by the Issuer to satisfy the tax liability in connection with the issuance of shares pursuant to the ESPP's "match benefit."

These shares were acquired under the Liberty Latin America Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).


Represents a sale effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 13, 2024.

These shares were sold in multiple transactions each at the price of $20.952342. The price reflected has been rounded to four decimal places.

/s/ Tracy Lowe, as power of attorney for Kristen N. Sieffert


Common Shares

For purposes of this disclosure, Canadian dollar amounts have been converted to U.S. dollars based on the Bank of Canada daily average exchange rate on August 1, 2025, CAN $1 = US $.724

Represents the conversion upon vesting of restricted share units into common shares of the Issuer. The restricted share units were awarded on August 1, 2024 and have a vesting schedule of 50% immediately and 50% on the first anniversary of the award date.


Class A Common Stock

Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Class A Common Stock, subject to the Reporting Person's continuous service to the Issuer at the time of vesting.

Represents the number of shares of Class A Common Stock that have been withheld by the Issuer to satisfy income tax withholding and remittance obligations in connection with the net settlement of the RSUs.

Subject to the Reporting Person's continuous service to the Issuer, the RSUs vest on the first, second, and third anniversaries of the transaction date (August 2, 2022).


Class A Common Stock


Adoption date of referenced 10b5-1(c) plan is: 03-06-2025


/s/ Heather Roemer, as attorney-in-fact for James J. Buquet III


John Uczekaj and Diane M. Uczekaj, as Community Property with ROS

Represents shares owed to the Reporting Person and his spouse pursuant to the terms of the Amendment to Satisfaction of Indebtedness and Satisfaction of Covenant Agreement dated June 30, 2025.

On July 3, 2025, the Reporting Person filed a Form 4 which inadvertently omitted this transaction.


Common Stock

167,322 shares consisting of 140,758 shares held in an account at Shareworks, 6,085 shares held in an account at Computershare, 11,097 shares held in a brokerage account, and 9,382 shares are held in a 401K plan.

43,000 restricted shares are held in an account at Computershare, which have upcoming vesting dates. 824 shares are dividend reinvested shares for a total of 43,824.

Vests 3,667 share(s) on 25-Feb-2017, 3,666 share(s) on 25-Feb-2018, 3,667 share(s) on 25-Feb-2019

95,000 stock options were granted under various dates and vesting periods of which all are currently exercisable.

James A. Hughes, POA Amanda Roche, Finance Department Supervisor/VP


Common stock issued to the Reporting Person in lieu of salary earned, during the three months ended July 31, 2025, less applicable withholding taxes and amounts required to be paid to the Reporting Person in cash pursuant to applicable law. The total shares of the Issuer's common stock issued to the Reporting Person was calculated by determining the salary earned by the Reporting Person during the three months ended July 31, 2025, less applicable withholding taxes and amounts required to be paid in cash to the Reporting Person pursuant to applicable law, and dividing the remainder by the closing price on July 31, 2025.


Phantom Stock units accrued under the Elevance Health, Inc. ("Company") Board of Directors Compensation Program.

The phantom stock units shall be payable in Company common stock upon the first to occur of (a) five years from the date of the annual meeting of shareholders that immediately precedes the Director's election date or (b) the date the Reporting Person ceases to be a member of the Company's board of directors, unless a later date is designated in the Reporting Person's election made under the Company's Board of Directors Deferred Compensation Plan.

/s/ Kathleen S. Kiefer, Attorney in fact


Common Stock

Common Stock

On August 1, 2025, U.S. Bounti, LLC and Local Bounti Corporation (the "Issuer") entered into an agreement (the "Purchase Agreement") under which U.S. Bounti, LLC purchased from the Issuer, for a combined purchase price of $10.0 million, (i) a convertible note with an initial principal balance of $10.0 million (the "Note") and (ii) a common stock purchase warrant (the "Warrant") pursuant to which U.S. Bounti, LLC has the right to purchase and acquire 550,000 shares of the Company's common stock, par value $0.0001 per share (the "Common Stock"). (Continued on Footnote 2).

(Continued from Footnote 1). Pursuant to the terms of the Purchase Agreement, U.S. Bounti, LLC will not have the right to receive, upon conversion of the Note or exercise of the Warrant, any shares of Common Stock if the issuance of such shares of Common Stock would exceed 221,031 shares, except that such limitation will not apply after the date that stockholder approval is obtained and deemed effective, as required by the rules and regulations of the New York Stock Exchange (the "Required Stockholder Approval"). The Issuer is required to seek the Required Stockholder Approval at a special stockholders meeting within three months of August 1, 2025.

Securities held by U.S. Bounti, LLC.


Represents the estimated number of share equivalents held by the reporting person in the unitized stock fund included in the Ameren Corporation Savings Investment Plan as of July 31, 2025.

Amount includes 611 accrued dividend equivalents acquired during the second quarter of 2025 pursuant to a dividend reinvestment feature of restricted stock units granted under the issuer's 2022 Omnibus Incentive Compensation Plan.

Jonathan T. Shade, Deputy Corp. Secy. of Ameren Corporation, attorney-in-fact for Michael L. Moehn


This price represents the weighted average price per share of common stock (each, a "Share") of Xylem Inc. (the "Issuer"). 1,800 Shares were executed at a range of prices from $143.63 to $143.65. The Reporting Person undertakes to provide, upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of Shares sold at each price.

/s/ Mike Nazario, by power of attorney for Victoria D. Harker


The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 20, 2025.

/s/ Christine Zhang, under Power of Attorney dated June 19, 2025, from Mark Kidd


Grant to reporting person of 1,698 shares of restricted stock. The shares vest in equal installments on August 4, 2026, April 30, 2027, and April 30, 2028.

Price is not applicable to grants of restricted stock.

After giving effect to the transactions reported in this Form 4, Mr. Fundler directly owns 1,698 shares of restricted stock of Build-A-Bear Workshop, Inc.


/s/ Raymond Myer, Attorney-in-Fact for Erin E. Hagen


The shares of Class A common stock were withheld to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units.

Represents 16,392 shares of Class A common stock held outright by the Reporting Person and 299,875 shares of Class A common stock subject to outstanding restricted stock units.

/s/ Sarah K. Wilson, as Attorney-in-Fact for Jeremy Fox-Geen


The sale of shares of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan adopted May 16, 2024 for tax and estate planning purposes.

The price reported above reflects the weighted average purchase price, rounded to the nearest hundredth. The highest price at which the shares were purchased was $20.93 and the lowest price at which the shares were purchased was $20.57. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote in this Form 4.

Dividend equivalent units ("DEUs") issued on restricted unit awards are included in the reporting person's common stock holding balance. Each DEU is the economic equivalent of one share of common stock of Annaly Capital Management, Inc. and payable in one share for each whole DEU.

/s/ Anthony C. Green, as Attorney-in-Fact
for David L. Finkelstein


Represents shares of Class B Common Stock withheld by the Issuer to cover taxes due by the Reporting Person upon a scheduled distribution of Class B Common Stock from the Issuer's Non-Qualified Deferred Compensation Plan.

/s/ Michael T. Fischette, Attorney-in-Fact


This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 27, 2024.


Represents 167,758 shares of Class A common stock held outright by the Reporting Person and 413,045 shares of Class A common stock subject to outstanding restricted stock units.

/s/ Sarah K. Wilson, as Attorney-in-Fact for Nikhil Chandhok


Mr. Dolci's aggregate remaining outstanding option, restricted share unit and common share balances following this transaction will be 6,188, 21,574 and 33,000 respectively.


Represents shares withheld to satisfy tax withholding obligations in connection with the vesting of restricted stock units.

/s/ Christopher Schaub, as attorney-in-fact for Kristin Wolfe


Represents deemed disposition of shares of common stock to the Issuer as a result of withholding of shares of common stock to satisfy tax withholding obligations in connection with vesting of RSUs issued in accordance with Rule 16b-3.

/s/ Michael A. Sherrick, Attorney-in-Fact


By reporting person as UTMA custodian for son

By reporting person as UTMA custodian for daughter

This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 18, 2025.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $267.06 to $267.76. The reporting person undertakes to provide to Burlington Stores, Inc., any security holder of Burlington Stores, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $270.66 to $271.44. The reporting person undertakes to provide to Burlington Stores, Inc., any security holder of Burlington Stores, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices of $272.14 and $272.21. The reporting person undertakes to provide to Burlington Stores, Inc., any security holder of Burlington Stores, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price set forth in this footnote to this Form 4.

/s/ Christopher Schaub, as attorney-in-fact for Jennifer Vecchio


These sales were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2025.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.27 to $36.26 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3).

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.27 to $36.71 inclusive.

Pursuant to an agreement between the Reporting Person and his former spouse, the Reporting Person has sole voting control over the shares. The Reporting Person has no pecuniary interest in the shares.


The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 21, 2025.

/s/ Christine Zhang, under Power of Attorney dated June 19, 2025, from Greg McIntosh


The shares of Class A common stock were withheld to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units.

Represents 92,070 shares of Class A common stock held outright by the Reporting person and 545,725 shares of Class A common stock subject to outstanding restricted stock units.

/s/ Sarah K. Wilson, as Attorney-in-Fact for Heath Tarbert


Represents 15,015 shares of Class A common stock held outright by the Reporting person and 79,430 shares of Class A common stock subject to outstanding restricted stock units.

/s/ Sarah K. Wilson, as Attorney-in-Fact for Tamara Schulz


Ordinary Shares

Restricted stock units ("RSUs") granted under the Cushman & Wakefield plc Second Amended & Restated 2018 Omnibus Non-Employee Director Share and Cash Incentive Plan convert into an equal number of ordinary shares of Cushman & Wakefield plc.

RSUs were granted on August 1, 2025 and vest and settle on the first anniversary of the grant date subject, with certain limited exceptions, to the reporting person's continuing board service through such vesting date.


The price reported is a weighted average price.  The prices ranged from $3.64 to $3.85, inclusive.  The Reporting Person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Cornick Family Investor, LLC is controlled by Mr. Cornick and his spouse, its managers, who have dispositive control and voting control over the shares held by Cornick Family Investor, LLC.


Class A Common Stock


Class A Common Stock

Class A Common Stock

Class A Common Stock

Class A Common Stock

Class A Common Stock

Class A Common Stock

Represents shares of Class A common stock held through an irrevocable non-grantor trust, of which the Reporting Person's legal counsel is the sole trustee and the Reporting Person's children are beneficiaries. The Reporting Person disclaims beneficial ownership of the shares of Class A common stock except to the extent of his pecuniary interest therein.

Each restricted stock unit represents a contingent right to receive one share of Class B common stock.

The restricted stock units vest in substantially equal monthly installments from July 1, 2025 through December 1, 2025, in each case, subject to the Reporting Person's continued service relationship with Circle Internet Group, Inc. through each applicable vesting date.

The restricted stock units vest in substantially equal monthly installments from July 1, 2025 through January 1, 2027, in each case, subject to the Reporting Person's continued service relationship with Circle Internet Group, Inc. through each applicable vesting date.

The restricted stock units vest in substantially equal monthly installments from July 1, 2025 through January 1, 2028, in each case, subject to the Reporting Person's continued service relationship with Circle Internet Group, Inc. through each applicable vesting date.

Each share of Class B common stock is convertible into Class A common stock on a one-for-one basis at the option of the Reporting Person. In addition, each share of Class B common stock will convert automatically into Class A common stock on a one-for-one basis upon any transfer of such share, except for certain permitted transfers described in the Issuer's Amended and Restated Certificate of Incorporation. Shares of Class B common stock do not expire.

The shares of Class B common stock were withheld to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units.

Represents shares of Class B Common Stock held through an irrevocable grantor trust, of which the Reporting Person is the sole trustee and the Reporting Person is beneficiary. The Reporting Person
is entitled to annuity payments from the trust, with any remaining assets to be distributed to the Allaire 2025 GRAT Remainder Trust, of which the Reporting Person's children are beneficiaries. The
Reporting Person disclaims beneficial ownership of the shares of Class B Common Stock except to the extent of his pecuniary interest therein.

/s/ Sarah K. Wilson, as Attorney-in-Fact for Jeremy Allaire


Proceeds from the sale will primarily be used to satisfy a divorce settlement.

The Reporting Person sold, in multiple transactions, common shares at prices ranging from $63.50 to $64.52.


/s/ Molly R. Benson, Attorney-in-Fact for Maryann T. Mannen


Represents shares withheld in connection with the vesting of restricted stock units to cover tax withholding obligations.

Robert J. Tannous by Power of Attorney for Eva C. Boratto


Represents the withholding of shares to satisfy tax withholding obligation.

/s/ Sonwha Lee as attorney-in-fact for Francis S. Soistman


Common Stock

Includes 73 shares acquired pursuant to The Hanover Insurance Group Inc.'s 2023 Employee Stock Purchase Plan on June 30, 2025.

The option, representing the right to purchase a total of 5,626 shares, vested 1/3 on each of 2/28/21, 2/28/22 and 2/28/23.

/s/ Lindsay L. Katz pursuant to Confirming Statement


This number represents shares of Class A Common Stock withheld to satisfy the tax withholding obligation due upon vesting of restricted stock units.

Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission.


Mr. Schottenstein disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.


The reporting person was granted restricted stock in lieu of a portion of his retainer fees for the remainder of the fiscal year ending January 31, 2026. The reporting person elected to receive $45,000 of his remaining fiscal year 2026 retainer fees in the form of the Issuer's common stock, par value $0.01 per share ("Common Stock"). The number of shares of restricted stock granted is based on a per share value of $13.35, the closing price of the Common Stock on the date of grant. The restricted stock vests on the first anniversary of the date of grant; provided, that the reporting person's service as a director is not terminated for cause prior to the vesting date.

The reporting person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock. These RSUs represent a 30% premium on the amount of retainer fees the reporting person has elected to receive in the form of equity in lieu of cash, as explained in the first footnote above. The number of RSUs granted is based on a per share value of $13.35, the closing price of the Common Stock on the date of grant. The RSUs vest on the first anniversary of the date of grant; provided, that the reporting person remains in continuous service through the vesting date.

/s/ Roger D. Shannon, by power of attorney


The reporting person was granted restricted stock in lieu of a portion of his retainer fees for the remainder of the fiscal year ending January 31, 2026. The reporting person elected to receive $41,375 of his remaining fiscal year 2026 retainer fees in the form of the Issuer's common stock, par value $0.01 per share ("Common Stock"). The number of shares of restricted stock granted is based on a per share value of $13.35, the closing price of the Common Stock on the date of grant. The restricted stock vests on the first anniversary of the date of grant; provided, that the reporting person's service as a director is not terminated for cause prior to the vesting date.


Class A Common Stock

Class A Common Stock

Stock options granted on August 1, 2025, under the Charter Communications, Inc. 2019 Stock Incentive Plan; 100% of the grant will vest on the third anniversary of the grant date, August 1, 2028.  Such options will terminate 10 years from the date of grant unless terminated sooner in accordance with the plan or grant agreement.

Restricted Stock Unit grant - price and expiration date not applicable.

Restricted Stock Units granted on August 1, 2025, under the Charter Communications, Inc. 2019 Stock Incentive Plan; 100% of the grant will vest on the third anniversary of the grant date, August 1, 2028.

/s/Jennifer A. Smith as attorney-in-fact for Richard J. DiGeronimo


The reporting person was granted restricted stock in lieu of a portion of her retainer fees for the remainder of the fiscal year ending January 31, 2026. The reporting person elected to receive $19,188 of her remaining fiscal year 2026 retainer fees in the form of the Issuer's common stock, par value $0.01 per share ("Common Stock"). The number of shares of restricted stock granted is based on a per share value of $13.35, the closing price of the Common Stock on the date of grant. The restricted stock vests on the first anniversary of the date of grant; provided, that the reporting person's service as a director is not terminated for cause prior to the vesting date.

Shares withheld by the Issuer to satisfy the reporting person's tax obligation in connection with the grant of restricted stock.


The reporting person was granted restricted stock in lieu of a portion of his retainer fees for the remainder of the fiscal year ending January 31, 2026. The reporting person elected to receive $11,625 of his remaining fiscal year 2026 retainer fees in the form of the Issuer's common stock, par value $0.01 per share ("Common Stock"). The number of shares of restricted stock granted is based on a per share value of $13.35, the closing price of the Common Stock on the date of grant. The restricted stock vests on the first anniversary of the date of grant; provided, that the reporting person's service as a director is not terminated for cause prior to the vesting date.


Common Stock

Each performance stock unit ("PSU") represents a contingent right to receive one share of the Issuer's common stock. The PSUs vest upon the Issuer's common stock achieving both a time-based vesting condition and a stock price performance-based vesting condition, both of which conditions must be satisfied before any PSU vests.

Represents shares sold to satisfy estimated tax withholding obligations upon the settlement of PSUs.

Represents the maximum number of shares remaining that may be issued pursuant to the PSUs.


The reporting person was granted restricted stock in lieu of a portion of her retainer fees for the remainder of the fiscal year ending January 31, 2026. The reporting person elected to receive $39,875 of her remaining fiscal year 2026 retainer fees in the form of the Issuer's common stock, par value $0.01 per share ("Common Stock"). The number of shares of restricted stock granted is based on a per share value of $13.35, the closing price of the Common Stock on the date of grant. The restricted stock vests on the first anniversary of the date of grant; provided, that the reporting person's service as a director is not terminated for cause prior to the vesting date.


Common Stock

Restricted stock unit ("RSU") award.  RSUs vest in equal installments on each of the first, second and third anniversaries of the grant date and are settled in shares of common stock on a one-for-one basis.

Prorated Annual Non-Qualified Stock Option ("Option") Award.  The Options become exercisable in substantially equal installments on each of the first, second, third and fourth anniversaries of the grant date.


Shares automatically withheld upon vesting of restricted stock to satisfy tax withholding obligations.


/s/ Roger D. Shannon, by Power of Attorney


Shares of common stock withheld by Issuer to satisfy tax withholding obligations on vesting of shares with restrictions from a grant issued on March 25, 2024.


Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Price reflected is the weighted average sale price for shares sold. The range of sales prices for the transactions reported was $123.09 - $123.15 per share. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

The options became fully exercisable on February 25, 2023, the third anniversary of the grant date.

The options became fully exercisable on February 23, 2024, the third anniversary of the grant date.

The options became fully exercisable on February 23, 2025, the third anniversary of the grant date.

One-third of the options became exercisable on February 28, 2024, an additional one-third of the options became exercisable on February 28, 2025 and the remaining one-third of the options will become exercisable on February 28, 2026, the third anniversary of the grant date.

One-third of the options became exercisable on February 27, 2025, an additional one-third of the options will become exercisable on February 27, 2026 and the remaining one-third of the options will become exercisable on February 27, 2027, the third anniversary of the grant date.

One-third of the options will become exercisable on February 25, 2026, an additional one-third of the options will become exercisable on February 25, 2027 and the remaining one-third of the options will become exercisable on February 25, 2028, the third anniversary of the grant date.

Anthony J. Salerno, Jr., Attorney-in-Fact


Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

This transaction involved a gift to a charitable donor-advised fund.

The options became fully exercisable on February 28, 2020, the third anniversary of the grant date.

The options became fully exercisable on February 26, 2022, the third anniversary of the grant date.

The options became fully exercisable on February 27, 2021, the third anniversary of the grant date.


Withholding of shares to cover taxes due in connection with the vesting of restricted stock units or performance share units, as applicable.

Shares represented by Company stock fund units under the Company Savings Plan based on information furnished by the Plan Administrator as of August 3, 2025.

/s/ Brett L. Eilander, Attorney-in-fact for Stephanie S. Marianos


Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of restricted stock units.

Includes 1,079 shares acquired under the Company's employee stock purchase plan on July 31, 2025.


Represents shares purchased in connection with an underwritten public offering of the Issuer's Common Stock that closed on August 1, 2025.

The securities reported in this row are directly beneficially owned by GV 2021, L.P. (the "2021 Partnership"). The general partner of the 2021 Partnership is GV 2021 GP, L.P. (the "2021 GP"). The general partner of the 2021 GP is GV 2021 GP, L.L.C. ("GV 2021 LLC"). The sole member of GV 2021 LLC is Alphabet Holdings LLC ("Alphabet Holdings"). The sole member of Alphabet Holdings is XXVI Holdings Inc. ("XXVI"). The controlling stockholder of XXVI is Alphabet Inc. Each of the 2021 GP, GV 2021 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to indirectly beneficially own (as the term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended) the securities directly beneficially owned by the 2021 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.


Grant of restricted common stock (the "Shares") pursuant to Issuer's 2020 Equity Incentive Plan. Such Shares were granted as part of Reporting Person's compensation for services as a non-employee director of Issuer for the period August 1, 2025 through July 31, 2026.

The Shares vest in four equal quarterly increments on October 31, 2025, January 31, 2026, April 30, 2026, and July 31, 2026. The last quarter of unvested shares will automatically vest as of the annual meeting of stockholders if Reporting Person either is not re-elected or is not nominated for re-election, and the annual meeting occurs before the final vesting of the grant.

Shares are held by a trust, of which the Reporting Person is trustee. Reporting Person disclaims beneficial ownership of Shares held by the trust except to the extent of their pecuniary interest therein.


The price in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.48 to $10.52, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.


Common Stock

Represents the weighted average sales price for price increments ranging from $261.46 to $262.21.  The Reporting Person undertakes to provide, upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

/s/ Wendy C. Skjerven, by power of attorney


The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.00 to $1.06. The reporting person undertakes to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within range set forth herein.

The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.05 to $1.065. The reporting person undertakes to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within range set forth herein.


Represents shares withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of shares of restricted common stock of the Issuer.

/s/Brent Takao, Attorney-in-Fact for Jeffrey J. Uttz


Represents 70,000 restricted stock units ("RSUs") which such RSUs shall vest in four substantially equal installments of the quarterly anniversaries of the grant date, provided that the reporting person remains employed by or is providing services to the Company.

/s/ Cara Soffer, Attorney-in-fact for Ezra Ernst


(a) President, Chief Executive Officer and Chairman of the Board of Directors.

/s/ Brent Takao, Attorney-in-Fact for Hajime Uba


Common Stock

Common Stock

Immediately prior to the closing of the Issuer's initial public offering, the shares of preferred stock of the Issuer automatically converted into shares of Common Stock on a one-for-0.052410901 basis.

LSV Associates II, LLC is the general partner of Lightstone Ventures II, L.P. ("LSV II") and Lightstone Ventures II (A), L.P. ("LSV II (A)") and has sole voting and dispositive power with respect to the shares held by LSV II and LSV II (A). The reporting person is a managing director of LSV Associates II, LLC, and shares voting and dispositive power with respect to the shares held of record by LSV II and LSV II (A). The reporting person disclaims beneficial ownership of such holdings, except to the extent of his pecuniary interest in the shares.

Following the transactions reported in this Form 4, (i) 1,781,479 shares of Common Stock are held by LSV II and (ii) 103,657 shares of Common Stock are held by LSV II (A).

Represents an award of restricted stock units ("RSUs"). The RSUs will vest on the earlier of the date of the annual meeting of stockholders to be held in 2026 or August 1, 2026. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date.

Consists of (i) 1,036,638 shares of Common Stock underlying Series C Preferred Stock and 492,833 shares of Common Stock underlying Series D Preferred Stock held by LSV II; and (ii) 60,333 shares of Common Stock underlying Series C Preferred Stock and 28,666 shares of Common Stock underlying Series D Preferred Stock held by LSV II (A).


Common Stock

Common Stock

Common Stock

Common Stock

Common Stock


Common Stock

Common Stock

LSV Associates II, LLC is the general partner of Lightstone Ventures II, L.P. ("LSV II") and Lightstone Ventures II (A), L.P. ("LSV II (A)") and has sole voting and dispositive power with respect to the shares held by LSV II and LSV II (A). The reporting person is a managing director of LSV Associates II, LLC, and shares voting and dispositive power with respect to the shares held of record by LSV II and LSV II (A). Jean George, Michael A. Carusi and Henry A. Plain, Jr. are the managing directors of LSV Associates II, LLC, and share voting and dispositive power with respect to the shares held of record by LSV II and LSV II (A). Mr. Carusi is a director of the Issuer and files separate Section 16 reports. Each of the reporting persons disclaims beneficial ownership of such shares except to the extent of his, her or its respective pecuniary interest therein.


Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Officer Title: Chief Customer Experience Officer


The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2024.

The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.44 to $13.00 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.


Common Stock


Common Stock

Common Stock

Held directly by Cooperatieve Gilde Healthcare V U.A. ("Gilde"). Gilde Healthcare V Management B.V. is the managing director of Gilde and has sole voting and dispositive power with respect to the shares held by Gilde. Gilde Healthcare V Management B.V. is owned by Gilde Healthcare Holding B.V. and managed by Edwin de Graaf and Pieter van der Meer. Geoff Pardo is a partner at Gilde and may be deemed to share voting and dispositive power with respect to the shares held of record by Gilde. Mr. Pardo disclaims beneficial ownership of such holdings, except to the extent of his pecuniary interest in the shares.


Common Stock

Common Stock

Common Stock


By U.S. Venture Partners Select Fund I-A, L.P.

Common Stock

Common Stock

Common Stock

Presidio Management Group XII, L.L.C. ("PMG XII") is the general partner of U.S. Venture Partners XII, L.P. ("USVP XII") and U.S. Venture Partners XII-A, L.P ("USVP XII-A") and has sole voting and dispositive power with respect to the shares held by USVP XII and USVP XII-A. The Reporting Person, Steven M. Krausz, Richard W. Lewis, Jonathan D. Root and Dafina Toncheva are the managing members of PMG XII, and share voting and dispositive power with respect to the shares held by USVP XII and USVP XII-A. Presidio Management Group Select Fund I, L.L.C. ("PMG Select") is the general partner of U.S. Venture Partners Select Fund I-A, L.P. ("USVP Select") and has sole voting and dispositive power with respect to the shares held by USVP Select.

The Reporting Person, Richard W. Lewis, Jonathan D. Root and Dafina Toncheva are the managing members of PMG Select and share voting and dispositive power with respect to the shares held by USVP Select. Each of the managing members of PMG XII and PMG Select disclaims beneficial ownership of such holdings, except to the extent of their pecuniary interest in the shares.

Consists of (i) 1,043,988 shares of Common Stock underlying Series C Preferred Stock, 496,309 shares of Common Stock underlying Series D Preferred Stock and 146,106 shares of Common Stock underlying Series E Preferred Stock held by USVP XII; (ii) 52,983 shares of Common Stock underlying Series C Preferred Stock, 25,189 shares of Common Stock underlying Series D Preferred Stock, and 7,415 shares of Common Stock underlying Series E Preferred Stock held by USVP XII-A; and (iii) 921,131 shares of Common Stock underlying Series E Preferred Stock held by U.S. Venture Partners Select Fund I, L.P. on its own behalf and as a nominee for USVP Select.


On August 1, 2024, the Reporting Person was granted restricted stock units ("RSUs") for 2,422.275 shares of KLA common stock. On August 1, 2025, twenty-five percent (25%) of the RSUs vested. Pursuant to the terms of the grant, shares of KLA common stock were automatically withheld at vesting to cover required tax withholding. The fair market value of KLA common stock used for purposes of calculating the number of shares to be withheld was the closing price of KLA common stock as reported on July 31, 2025.

The number of shares of KLA common stock includes 7,853.775 shares issuable upon vesting of RSUs.

/s/ Jeffrey S. Cannon, as attorney-in-fact for Brian Lorig


Class A Common Stock

Class A Common Stock

Shares of Class B Common Stock were converted at a 1:1 ratio for a share of Class A Common Stock at the election of the Reporting Person.

The shares are held directly by The ST Trust under agreement dated October 2, 2019, for which the Reporting Person serves as trustee.

The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024.

This sale price represents the weighted average sale price of the shares sold ranging from $242.25 to $243.24 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

This sale price represents the weighted average sale price of the shares sold ranging from $243.31 to $244.23 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

This sale price represents the weighted average sale price of the shares sold ranging from $244.31 to $245.22 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

This sale price represents the weighted average sale price of the shares sold ranging from $245.36 to $246.24 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

This sale price represents the weighted average sale price of the shares sold ranging from $246.36 to $247.35 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

This sale price represents the weighted average sale price of the shares sold ranging from $247.36 to $248.33 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

This sale price represents the weighted average sale price of the shares sold ranging from $248.37 to $249.17 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date.

/s/ Kimberly Hackman, by power of attorney


On August 1, 2024, the Reporting Person was granted restricted stock units ("RSUs") for 10,658.011 shares of KLA common stock. On August 1, 2025, twenty-five percent (25%) of the RSUs vested. Pursuant to the terms of the grant, shares of KLA common stock were automatically withheld at vesting to cover required tax withholding. The fair market value of KLA common stock used for purposes of calculating the number of shares to be withheld was the closing price of KLA common stock as reported on July 31, 2025.

The number of shares of KLA common stock includes 51,587.511 shares issuable upon vesting of RSUs.

/s/ Jeffrey S. Cannon, as attorney-in-fact for Richard P. Wallace


On August 1, 2024, the Reporting Person was granted restricted stock units ("RSUs") for 3,633.412 shares of KLA common stock. On August 1, 2025, twenty-five percent (25%) of the RSUs vested. Pursuant to the terms of the grant, shares of KLA common stock were automatically withheld at vesting to cover required tax withholding. The fair market value of KLA common stock used for purposes of calculating the number of shares to be withheld was the closing price of KLA common stock as reported on July 31, 2025.

The number of shares of KLA common stock includes 16,950.912 shares issuable upon vesting of RSUs.

/s/ Jeffrey S. Cannon, as attorney-in-fact for Ahmad A. Khan


On August 1, 2024, the Reporting Person was granted restricted stock units ("RSUs") for 432.981 shares of KLA common stock. On August 1, 2025, twenty-five percent (25%) of the RSUs vested. Pursuant to the terms of the grant, shares of KLA common stock were automatically withheld at vesting to cover required tax withholding. The fair market value of KLA common stock used for purposes of calculating the number of shares to be withheld was the closing price of KLA common stock as reported on July 31, 2025.

The number of shares of KLA common stock includes 2,206.000 shares issuable upon vesting of RSUs.

/s/ Jeffrey S. Cannon, as attorney-in-fact for Virendra A. Kirloskar


On August 1, 2024, the Reporting Person was granted restricted stock units ("RSUs") for 1,271.694 shares of KLA common stock. On August 1, 2025, twenty-five percent (25%) of the RSUs vested. Pursuant to the terms of the grant, shares of KLA common stock were automatically withheld at vesting to cover required tax withholding. The fair market value of KLA common stock used for purposes of calculating the number of shares to be withheld was the closing price of KLA common stock as reported on July 31, 2025.

The number of shares of KLA common stock includes 6,778.194 shares issuable upon vesting of RSUs.

/s/ Jeffrey S. Cannon, as attorney-in-fact for Mary Beth Wilkinson


Class A Common Stock

Class A Common Stock

Shares of Class B Common Stock were converted at a 1:1 ratio for a share of Class A Common Stock at the election of the Reporting Person.

The shares are held by The AF Living Trust UTA dated 9/4/19 for which the Reporting Person serves as the trustee.

The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan that was adopted on March 6, 2025.

This sale price represents the weighted average sale price of the shares sold ranging from $242.18 to $243.11 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

This sale price represents the weighted average sale price of the shares sold ranging from $243.54 to $244.49 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

This sale price represents the weighted average sale price of the shares sold ranging from $244.68 to $245.57 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

This sale price represents the weighted average sale price of the shares sold ranging from $245.70 to $246.69 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

This sale price represents the weighted average sale price of the shares sold ranging from $246.76 to $247.75 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

This sale price represents the weighted average sale price of the shares sold ranging from $247.76 to $248.75 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

This sale price represents the weighted average sale price of the shares sold ranging from $248.78 to $249.24 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

Certain of these securities are represented by restricted stock units.

Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date.


On August 1, 2024, the Reporting Person was granted restricted stock units ("RSUs") for 3,633.412 shares of KLA common stock. On August 1, 2025, twenty-five percent (25%) of the RSUs vested. Pursuant to the terms of the grant, shares of KLA common stock were automatically withheld at vesting to cover required tax withholding. The fair market value of KLA common stock used for purposes of calculating the number of shares to be withheld was the closing price of KLA common stock as reported on July 31, 2025.

The number of shares of KLA common stock includes 16,160.912 shares issuable upon vesting of RSUs.

/s/ Jeffrey S. Cannon, as attorney-in-fact for Bren D. Higgins


Ordinary Shares

The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.13 to $15.31, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Restricted share units were granted on August 1, 2024, with 12,827 vested on August 1, 2025, 12,827 vesting on each of August 1, 2026 and August 1, 2027, and 12,830 vesting on August 1, 2028.

Executive Vice President, Chief Human Resources Officer.

/s/ Dov Bergwerk as attorney-in-fact for Placid Jover


Vested shares under the Willis Towers Watson Non-Qualified Stable Value Excess Plan for U.S. Employees settle for Ordinary Shares, nominal value $0.000304635 per share, on a 1:1 basis on the first business day of the month on which the NASDAQ Stock Market is open for business following the earlier of (i) the date that is 6 months after the reporting person's separation from service and (ii) the date that is 30 days after the reporting person's death.

Includes restricted share units credited to the participant's account by the Company pursuant to the Willis Towers Watson Non-Qualified Stable Value Excess Plan for U.S. Employees (the "Plan") accrual formula, net of the units acquired pursuant to the participant's contribution under the Plan.

/s/ Carl A. Hess by Lina Vanessa Jaramillo, Attorney-in-Fact (power of attorney previously filed)


The 56,737 shares were sold through a number of separate trades, with sales price ranging from $21.80 to $21.87, and a weighted average sales price of $21.84.  The reporting person undertakes to provide, upon request by the Staff of the Securities and Exchange Commission, the issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

The 7,015 shares were sold through a number of separate trades, with sales price ranging from $21.80 to $21.81, and a weighted average sales price of $21.80.  The reporting person undertakes to provide, upon request by the Staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

/s/Philip R. Martens, by Laura Lynn Church, Attorney-in-Fact


Reflects withholding of shares by the Company to cover tax withholding obligations on the vesting of restricted stock awards under the Company's Second Amended and Restated 2009 Equity Incentive Plan.

The amount of securities owned following the reported transaction reflects direct ownership of all shares of common stock, including restricted shares.

Lee N. Davis, as attorney-in-fact under Power of Attorney dated June 20, 2024


Required number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 25,000 shares of Common Stock underlying RSUs granted to the Reporting Person on July 29, 2024. These sales were automatically executed pursuant to an irrevocable election by the Reporting Person to satisfy tax withholding obligations through "sell-to-cover" transactions and were not made at the discretion of the Reporting Person.

Represents the weighted average sale price of the shares sold ranging from $1.045 to $1.075 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth in this footnote.


The reported sale was effected pursuant to a Rule 10b5-1(c) trading plan adopted on February 10, 2025.

Represents (i) 39,859 shares or units of restricted stock, of which 5,737 are vested, (ii) 48,973 shares of Common Stock underlying PSUs, all of which are vested, and (iii) 3,719 shares of Common Stock purchased under the Issuer's Employee Stock Purchase Plan.


/s/ Julie J. Gebauer by Lina Vanessa Jaramillo, Attorney-in-Fact (power of attorney previously filed)


By: /s/ Daniel M. Bauer, as attorney-in-fact


Represents the weighted average sale price of the shares sold ranging from $1.04 to $1.07 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth in this footnote.


Ordinary Shares

The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 15, 2024.

Restricted share units were granted on August 1, 2022, with 52,742 vested on each of August 1, 2023, August 1, 2024 and August 1, 2025, and 52,744 vesting on August 1, 2026.

Executive Vice President, Global R&D and Chief Medical Officer

/s/ Dov Bergwerk as attorney-in-fact for Eric A. Hughes


Received pursuant to Issuer's Directors' Stock Award Plan for service as a director - exempt transaction under Rule 16b-3 (d).

N/A.

/s/ Andres C. Ferrero , Attorney-in-Fact


Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 23,377 restricted stock units that were awarded in lieu of cash compensation that would otherwise have been owed to the reporting person. No shares were sold by the reporting person or VolitionRx in such transaction.

These shares of common stock are jointly owned by the reporting person and his spouse.


Represents shares held by the Irrevocable Trust of Rose Dempsey, of which the reporting person has sole voting and dispositive power


Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 13,069 restricted stock units that were awarded in lieu of cash compensation that would otherwise have been owed to the reporting person. No shares were sold by the reporting person or VolitionRx in such transaction.


Grant of of restricted common stock (the "Shares") pursuant to Issuer's 2020 Equity Incentive Plan. Such Shares were granted as part of Reporting Person's compensation for services as a non-employee director of Issuer for the period August 1, 2025 through July 31, 2026.

The Shares vest in four equal quarterly increments on October 31, 2025, January 31, 2026, April 30, 2026, and July 31, 2026. The last quarter of unvested shares will automatically vest as of the annual meeting of stockholders if Reporting Person either is not re-elected or is not nominated for re-election, and the annual meeting occurs before the final vesting of the grant.

Shares are held by a trust, of which the Reporting Person disclaims beneficial ownership of Shares held by the trust except to the extent of their pecuniary interest therein.


Vested shares under the Willis Towers Watson Non-Qualified Stable Value Excess Plan for U.S. Employees settle for Ordinary Shares, nominal value $0.000304635 per share, on a 1:1 basis on the first business day of the month on which the NASDAQ Stock Market is open for business following the earlier of (i) the date that is 6 months after the reporting person's separation from service and (ii) the date that is 30 days after the reporting person's death.

Includes restricted share units credited to the participant's account by the Company pursuant to the Willis Towers Watson Non-Qualified Stable Value Excess Plan for U.S. Employees (the "Plan") accrual formula, net of the units acquired pursuant to the participant's contribution under the Plan.

/s/ Andrew Krasner by Lina Vanessa Jaramillo, Attorney-in-Fact (power of attorney previously filed)


Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 18,341 restricted stock units that were awarded in lieu of cash compensation that would otherwise have been owed to the reporting person. No shares were sold by the reporting person or VolitionRx in such transaction.


Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 16,086 restricted stock units that were awarded in lieu of cash compensation that would otherwise have been owed to the reporting person. No shares were sold by the reporting person or VolitionRx in such transaction.